Advances in Cancer Research: Volume 119
12%
off

Advances in Cancer Research: Volume 119

Edited by  , Edited by 

Free delivery worldwide

Available. Dispatched from the UK in 2 business days
When will my order arrive?

Description

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.
show more

Product details

  • Hardback | 504 pages
  • 158 x 230 x 30mm | 939.99g
  • Academic Press Inc
  • San Diego, United States
  • English
  • 0124071902
  • 9780124071902

Table of contents

Vaccines for Cancer: Past, Present and Future

Understanding the role of Ets-mediated gene regulation in complex biological processes

Non-Small Cell Lung Cancer

Mitochondrial Alterations During Carinogenesis

Human polynucleotide phosphorylase (hPNPaseold-35): should I eat you or not- that is the question?
show more

Review quote

Praise for the Serial "This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences." --American Scientist "Excellent, highly informative, in-depth reviews...expertly written, up-to-date, and well-referenced." --Journal of Medicinal Chemistry "This is a series that has a long tradition of excellence in the field of cancer biology." --Doody's Publishing Reviews
show more

About Kenneth D Tew

Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
show more